London-based biotech firm BoobyBiome has raised €2.8 million in Seed funding. DeepTech investor Empirical Ventures led the round, supporting the company's advanced breast milk microbiome research. This investment facilitates international scaling of its infant feeding solutions.
BoobyBiome, founded in 2019 by female scientists, addresses rising infant health issues. The company leverages the breast milk microbiome to combat conditions like food allergies and asthma. Furthermore, it aims to bridge health gaps for babies unable to exclusively breastfeed.
The startup developed the world's largest high-resolution breast milk microbiome database. This extensive research, conducted at UCL Great Ormond Street Institute of Child Health, underpins its innovations. Consequently, BoobyBiome identified and preserved beneficial bacterial strains crucial for infant gut and immune development.
BoobyBiome engineered two key solutions. First, a patented device enhances stored breast milk quality, preserving its natural microbiome and nutrients. This innovation followed discoveries about oxygen removal during storage. Second, the company develops a live microbiome drop. This drop, derived from breast milk bacteria, supports developing microbiomes in formula-fed, C-section, or preterm infants. Companies like Danone and Nestlé also explore infant nutrition advancements.
The new capital will advance the commercial launch of BoobyBiome’s storage device. It will also fund ongoing research and development for the live microbiome drop. Moreover, the company plans to expand its commercial team for international growth, a common goal for startups receiving biotech funding.
